Results

Patients initiating nivolumab or pembrolizumab on or after September 1, 2015, were eligible for inclusion, Table 1. Exclusion criteria by patient selection phase

Studied design

Patients were eligible for this analysis if they had a diagnosis of HN cancer (any histology) and initiated an I-O agent between September 1, 2015, and September 30, 2017.

From index date backwards to the first Date of first I-O agent received within the enrollment period

From index date until earliest of report of death, end of progress notes (21.5%), and death (13.8%).

Baseline comorbidities, n (%)

Table 1. Baseline demographics and clinical characteristics

Baseline demographics and clinical characteristics

Table 2. Patient baseline demographics and clinical characteristics*

*Excluding patients with unknown I-O agent at index date.

From index date until earliest of report of death, end of progress notes (21.5%), and death (13.8%).

Figure 4. Kaplan–Meier estimate of rwOS after first I-O agent by line of therapy

Figure 5. Kaplan–Meier estimate of rwOS after first I-O agent by line of therapy

Table 3. Index I-O treatment characteristics

Table 4. Subsequent treatments received after index I-O agent treatment discontinuation*

